Platelet cytochrome c-oxidase activity in patients with acute schizophrenia in the course of their treatment with risperidone

Objectives: Testing a hypothesis, that platelet cytochrome c-oxidase (COX) activities in patients with paranoid schizophrenia, acute episode, may be linked to dynamics of their clinical patterns and quality of cognitive functioning under antipsychotic treatment. Methods: Psychopatho-logical (PANSS, NSA-16) and cognitive assess-ments;platelet COX enzymatic activity determination, post-hoc nonparametric statistical analysis. Results: Psychopathological and cognitive assessments were done and blood was sampled in patients before (at baseline) and after treatment with risperidone. Following regu- larities were found after the treatment of patients: Significant elevation of COX, wherein the higher was COX at baseline, the more prominent was decrease in PANSSneg and NSA rates;significant negative correlation between COX and executive time in cognitive tests. When the patient group was divided by median of COX at baseline into two subgroups (greater or equal median, and 20% was assigned to the first subgroup;significantly larger amount of patients with PANSSneg by <20% was assigned to the second group. Conclusions: Therapy with risperidone seems to be more effective for patients with higher COX activity at baseline, but this fact requires further study.

Different effects of paliperidone and risperidone therapy on blood lipid and Hcy metabolism as well as endocrine hormones in patients with schizophrenia

Objective: To explore the different effects of paliperidone and risperidone therapy on blood lipid and Hcy metabolism as well as endocrine hormones in patients with schizophrenia. Methods: A total of 118 patients with schizophrenia who were treated in the hospital between December 2014 and February 2017 were collected as the research subjects and divided into control group and study group by random number table, each group with 59 cases. Control group received risperidone therapy, observation group received paliperidone therapy, and the differences in the levels of blood lipid indexes, Hcy metabolism indexes and endocrine hormones were compared between the two groups before and after treatment. Results:There was no statistically significant difference in the levels of blood lipid indexes, Hcy and endocrine hormones between the two groups before treatment. After treatment, lipid indexes TG and TC levels in peripheral blood of study group were lower than those of control group while HDL-C content was higher than that of control group;Hcy level in serum of study group was lower than that of control group;endocrine hormones FT3, FT4, T and E2 levels in serum of study group were higher than those of control group. Conclusion: paliperidone therapy for schizophrenia can be more effective than risperidone in regulating blood lipid metabolism, Hcy metabolism and endocrine hormones.

Correlation of hair risperidone concentration and serum level among patients with schizophrenia

Background Risperidone (RSP) has a rapid onset in vivo, low dosage and high plasma protein binding rate, therefore therapeutic drug monitoring (TDM) is needed to ensure safety in clinical treatment. However, compared with blood, hair is non-invasive, safe, non-infectious and easy to transport and store. Aims This study aims to investigate the correlations among the drug concentrations of RSP in hair and serum, which provides an experimental basis to explore hair as a novel biomaterial to meet the needs of clinical detection. Methods 34 patients with schizophrenia treated with RSP for more than 3 months were enrolled in this study. About 1 cm section of hair near the scalp was taken from the subjects, pretreated and detected by liquid chromatography-mass spectrometry. A correlation analysis was conducted among the drug concentrations in hair, the serum concentrations and the daily dosage. The data were analysed usi叩 SPSS 20.0 software. Results There was significant correlation between the hair concentration of RSP (two-tailed test, r=0.440, p=0.009) with the serum concentration of RSP, and the hair concentration of 9-hydroxyrisperidone (9-HR) with the serum concentration of 9-HR had no significant correlation (two-tailed test, r=-0.217, p=0.217);the total concentration of the RSP and 9-HR had no significant correlation between hair and serum (r=0.227, p=0.196). The dosage had no statistically significant correlation with the concentration of RSP in hair (r=0.207, p=0.241), 9-HR in hair (r=-0.194, p=0.271) and the total concentration of RSP and 9-HR in hair (r=0.188, p=0.288). There was no statistical correlation between the dosage and the concentration of RSP in serum (r=-0.059, p=0.741), but significant correlation between the dosage and 9-HR in serum (r=0.581 p<0.001) was found, and the correlation between the dosage and the total concentration of the two drugs RSP and 9-HR in serum was also significant (r=0.437, p=0.01). Conclusion The correlation analysis showed that the concentration of RSP in hair was statistically significant with the serum RSP concentration. In this study, we provided some experimental basis for hair as a new biomaterial to monitor the therapeutic drug concentration.

A meta-analysis of phlegm-resolving Chinese medicine combined with risperidone for treatment of schizophrenia

Objective:The efficacy and occurrence of adverse reactions of prescriptions containing phlegm-resolving Chinese medicine combined with risperidone in the treatment of schizophrenia were retrospectively studied by means of meta-analysis.Methods:A variety of different Chinese and English databases were searched from January 1,2000 to May 1,2020.Review Manager 5.3 software was used to evaluate the methodological quality of the included studies.The positive and negative symptom scale(PANSS)was used as the evaluation standard to analyze the total scores,positive scores,negative scores and general psychopathological scores,clinical efficacy and safety of prescriptions containing phlegmresolving Chinese medicine combined with risperidone of schizophrenia.The heterogeneity test and sensitivity analysis were also carried out by Review Manager 5.3,and the potential publication bias was analyzed by"funnel plot".Results:A total of 1515 patients were included in 15 studies.Compared with control group of risperidone alone,the total PANSS scale score,positive symptom score,negative symptom score and general psychopathological score of the treatment group of phlegm-resolving Chinese medicine combined with risperidone were all lower than those of the control group(P=0.01,MD=-6.35,95%CI[-11.29,-1.40]),(P=0.04,MD=-1.42,95%CI[-2.74,-0.09]),(P<0.01,MD=-2.16,95%CI[-3.41,-0.91]),and(P<0.01,MD=-3.80,95%CI[-6.37,-1.24]),the clinical efficacy of phlegm-resolving Chinese medicine combined with risperidone treatment group on schizophrenia was better than that of the control group[P<0.01,RR=1.09,95%CI(1.05-1.13)].The incidence of adverse reactions was reduced(P=0.02,RR=0.56,95%CI[0.34-0.93]).Conclusion:The combination of prescriptions containing phlegm-resolving Chinese medicine and risperidone can effectively improve the efficacy of patients with schizophrenia and reduce the occurrence of adverse drug reactions compared with risperidone alone.

Evaluation of serum indexes and electrophysiological characteristics after ziprasidone combined with modified electroconvulsive therapy for schizophrenian

Objective:To study the effect of ziprasidone combined with modified electroconvulsive therapy (MECT) on serum indexes and electrophysiological characteristics of schizophrenia. Methods: A total of 44 patients with schizophrenia treated in our hospital between May 2014 and July 2016 were selected and randomly divided into MECT group and control group, MECT group received ziprasidone combined with MECT therapy and control group received ziprasidone therapy. Before treatment as well as 1 month, 2 months and 3 months after treatment, serum nerve cytokine levels and inflammatory factor levels as well as nerve electrophysiology parameters were detected.Results: 1 month, 2 months and 3 months after treatment, serum BDNF, GDNF and NGF levels of both groups were significantly higher than those before treatment, IL-1β, IL-6, IL-17 and TNF-α levels were significantly lower than those before treatment, P300 and N2-P3 latency were significantly shorter than those before treatment, and P300 and N2-P3 amplitude were significantly higher than those before treatment;serum BDNF, GDNF and NGF levels of MECT group were significantly higher than those of control group, IL-1β, IL-6, IL-17 and TNF-α levels were significantly lower than those of control group, P300 and N2-P3 latency were significantly shorter than those of control group, and P300 and N2-P3 amplitude were significantly higher than those of control group.Conclusion: Ziprasidone combined with modified electroconvulsive therapy can improve neuron function, reduce neuron damage and adjust nerve electrophysiology function.

Effect of berberine combined with risperidone therapy on endocrine hormones and oxidative stress in patients with schizophrenia

Objective:To study the effect of berberine combined with risperidone therapy on endocrine hormones and oxidative stress in patients with schizophrenia.Methods: A total of 90 patients with schizophrenia who were treated in our hospital between May 2014 and May 2016 were collected, reviewed and then divided into the control group (n=47) who received risperidone therapy and the observation group (n=47) who received berberine combined with risperidone therapy. Serum insulin resistance index levels, thyroid hormone and prolactin contents as well as oxidative stress index contents before and after treatment were compared between two groups of patients.Results: Before treatment, differences in serum insulin resistance index levels, thyroid hormone and prolactin contents as well as oxidative stress index contents were not statistically significant between two groups of patients. After treatment, serum FINS and HOMA-IR levels in observation group were lower than those in control group;serum T3 content was higher than that in control group while PRL content was lower than that in control group;serum MDA content was lower than that in control group while SOD, GSH-Px and CAT contents were higher than those in control group.Conclusion: Berberine combined with risperidone therapy for patients with schizophrenia won't cause severe endocrine hormone level disorder, and helps to reduce the systemic oxidative stress response.

Effect of ziprasidone on QTc interval in Chinese patients with schizophrenia

Objective: To investigate the effect of ziprasidone on QTc in Chinese patients with schizophrenia. Methods: The study involved 27 patients with schizophrenia. Ziprasidone was initiated with 40 mg/day. From day 3 to day 7, the dose was increased gradually to 120-160 mg/d according to the effectiveness and tolerability. QTc values were measured at the beginning and month 6. Results: At the beginning of the 6 months treatment, the mean QTc interval of patients was(387.5±19.0) ms. At the end of the study, it was(402.9±23.6) ms. The difference has statistically significance(P<0.05). The mean QTc interval changed significantly throughout 6-months period but no one exceed the QTc dangerous limits. Significant correlation was found between QTc interval and the dose. Conclusion: In summary, our results suggest that ziprasidone has good tolerance in patient with schizophrenia despite its dose-related QTc prolongation. Ziprasidone have no pro-arrhythmic profile.

Relationship between plasma risperidone concentrations and clinical features in chronic schizophrenic patients in China

BACKGROUND Prior studies have noted great variability in the plasma levels of risperidone(RIS).Plasma concentrations of RIS and its active moiety are highly variable and depend on absorption,metabolism,and other predictors of metabolic dysregulation;however,these factors are poorly understood and the association between metabolic change and change in psychopathology is uncertain.AIM To ascertain the characteristics of chronic schizophrenic patients treated with RIS,and to assess their relationship with plasma RIS levels.METHODS This was a descriptive cross-sectional study of 50 patients with a diagnosis of schizophrenic psychosis treated with RIS in a psychiatric service.The plasma concentrations of RIS and its metabolite 9-hydroxyrisperidone were determined by high performance liquid chromatography.The patients’demographic and clinical characteristics,and psychopathologies were assessed,and the associations between clinical variables and plasma levels of RIS were explored.RESULTS Male patients received higher doses of RIS than female ones,but plasma concentrations of RIS and risperidone+9-hydroxyrisperidone(active moiety)were higher in female patients.Age and the mean scores of the general psychopathology subscale of the Positive and Negative Syndrome Scale(PANSS)were significantly positively correlated with plasma concentrations of risperidone+9-hydroxyrisperidone adjusted for weight and dose in all 50 subjects.In male subjects,we found a statistically significant positive correlation between the concentrations of risperidone+9-hydroxyrisperidone in plasma/(dose×kg)and age,mean PANSS negative subscale scores,mean PANSS general psychopathology subscale scores,and mean PANSS total scores.CONCLUSION Long-term use of RIS should be closely monitored in older patients and females to minimize the risk of high concentrations which could induce side effects.

MiRNA-365 and miRNA-520c-3p respond to risperidone treatment in first-episode schizophrenia after a 1 year remission

Background MicroRNAs （miRNAs） control gene expression by destabilizing target transcripts and inhibiting their translation. Aberrant expression of miRNAs has been described in many human diseases, including schizophrenia. However, the effects on miRNA expression in response to antipsychotic treatment in peripheral circulation have not been thoroughly examined. Methods Using quantitative real-time PCR （qRT-PCR）, We quantified the expression of seven candidate miRNAs in plasma samples of 40 first-episode schizophrenics before and after antipsychotic treatment. The patients were all treated with risperidone and achieved remission in 1 year. Results Compared with the baseline, the expression levels of miR-365 and miR-520c-3p were significantly down- regulated after 1 year of risperidone treatment （P 〈0.001）. There were no significant correlations between the clinical symptoms and the expression levels of these two miRNAs （P 〉0.05）. Conclusions This study analyzed possible circulating miRNAs in response to antipsychotic monotherapy for schizophrenia, the further mechanism need to be confirmed.

Effects of combination pharmacotherapy and social skills training for schizophrenia: A randomized controlled trial

Pharmaco-psychosocial treatment (PPST) refers to a treatment paradigm combining pharmacotherapy with psychosocial therapy. We conducted an 18-month randomized controlled tracking study to evaluate the efficacy of social skills training (SST) in 11 individuals with schizophrenia on risperidone monotherapy. They were randomized to either SST or non-SST group, and Global Assessment Functioning (GAF) and Brief Psychiatric Rating Scale (BPRS) scores in the 2 groups showed gradual improvement. In the SST group, Digit Span Distraction Test (DSDT) at 12 and 18 months showed significant improvement. The Subjective Deficit Syndrome Scale (SDSS) scores in the SST group showed significant improvement after 6 months and showed a significant difference in comparison between the groups. After the subjective feeling of health was recovered, the items of motivation were recovered as a direct effect of SST. Some items of the Life Assessment Scale for the Mentally Ill (LASMI) score showed significant improvement (or significant trend) in only the SST group after 6 months. Items of daily life, work skills, and self-recognition were continuously improved. We report 2 cases in the SST group that had DSDT improvement in parallel with change of action and communication as a change of social function. This study is only exploratory due to the small number of cases. However, we have demonstrated potential improvement in cognitive function due to learning experiences that required working memory and attention, thus providing improvement in social life.

A Study on the Effect of Risperidone on PPI and P50 Deficit in FirstEpisode and Chronic Patients with Schizophrenia

Objective To investigate the effect of atypical antipsychotics risperidone on prepulse inhibition of the startle reflex(PPI) and P50 deficit in first-episode and chronic patients with schizophrenia. Methods PPI and P50 were tested and compared in 81 first-episode acute schizophrenia patients and 92 chronic schizophrenia patients before and after the risperidone. Results There was no significant difference in PPI and P50 indices between the two groups before treatment(P>0. 05); 2) there was no significant correlation between PPI & P50 inhibition indices and PANSS score, onset frequency and disease course(P>0.05); 3) Except the significant group main effect for S2 amplitude in P50(P=0. 02), there was no significant change for main effect and interaction of the other P50 and PPI inhibition ratio indices after treatment(P>0. 05). The effect of risperidone on PPI and P50 measurement index had nothing to do with the curative effect. Conclusion There exists a deficit in sensory gating inhibition in both first-episode schizophrenia and chronic schizophrenia, which is relatively independent from disease course. The risperidone is not effective in improving PPI and P50 inhibition deficit.

Long-Term Clinical Outcome of Patients Using Risperidone Long-Acting Injectable: The Romanian e-STAR Database

The objectives of e-STAR Romania (NCT00283517) were to collect clinical outcome data of Romania schizophrenia or schizo-affective disorder patients;prospectively to assess the reasons of treatment initiation, medication usage patterns;to document (long-term) clinical efficacy;and to collect safety data, as well as recording 2-year corresponding retrospective data. In total, 378 eligible subjects were enrolled who were initiated either on risperidone long-acting injectable (RLAI) (290) or on an oral antipsychotic (OA) (88) at baseline as required by the local Summary of the Product Characteristics. Data were collected from per patient both retrospectively and prospectively over a 24-month period at 3-month intervals after starting treatment. The results indicated that subjects suffering from schizophrenia or schizo-affective disorder initiated on RLAI were less likely to be hospitalized within the first 24 months after the initiation of treatment. Moreover, subjects treated with RLAI experienced significant improvements in their illness severity and functioning. Discontinuation rates for RLAI were low and doses were stable throughout the 24 months following the initiation of treatment. In addition, the necessity for supplementary concomitant medication was reduced. Adverse events were reported in 20.3% (RLAI) and 11.4% (OA) of the subjects. In general, patients initiated on RLAI and OA at baseline both clinically improved on all assessed parameters but a larger improvement was observed for patients on RLAI. Incidences of reported AEs during the use of RLAI in a naturalistic setting are comparable with those described in clinical studies;however, the incidence of extrapyramidal signs and weight gain was lower than expected.

氯丙嗪联合利培酮治疗首发精神分裂症的效果及对甲状腺功能的影响

目的:探讨氯丙嗪联合利培酮治疗首发精神分裂症的效果及对甲状腺功能的影响。方法:选取2022年6月-2023年6月南通市第四人民医院收治的首发精神分裂症患者80例为研究对象,以随机摸球法将其分为对照组和观察组,各40例。对照组采用氯丙嗪治疗,观察组在对照组基础上采用利培酮治疗。比较两组疗效、甲状腺激素[血清三碘甲状腺原氨酸(T3)、甲状腺素(T4)、游离三碘甲状腺原氨酸(FT3)、游离甲状腺素(FT4)]。结果:观察组疗效总有效率高于对照组,差异有统计学意义(P=0.043)。治疗前,两组T3、T4、FT3、FT4水平比较,差异无统计学意义(P>0.05);治疗后,两组T3、T4、FT3、FT4水平降低,观察组高于对照组,差异有统计学意义(P<0.05)。结论:氯丙嗪联合利培酮治疗首发精神分裂症效果较好,对甲状腺功能的影响较小,值得临床应用。

氯氮平联合齐拉西酮治疗精神分裂症患者的效果

目的:探讨氯氮平联合齐拉西酮治疗精神分裂症患者的效果。方法:选择2021年6月—2023年8月黄山市第二人民医院收治的80例精神分裂症患者作为研究对象,通过随机数表法将患者分为对照组与观察组,各40例。对照组采用氯氮平联合利培酮治疗,观察组采用氯氮平联合齐拉西酮治疗,比较两组精神状况[简明精神病评定量表(BPRS)、社会功能缺陷量表(SDSS)、治疗时出现的症状量表(TESS)]、肾功能指标、血脂水平、血清水平及糖代谢。结果:两组治疗前SDSS评分、血脂水平、载脂蛋白B(Apo-B)水平、糖代谢指标比较,差异无统计学意义(P>0.05);观察组治疗后SDSS评分、TESS评分、总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、Apo-B、前白蛋白(PA)、糖化血清蛋白(GSP)、空腹血糖(FBG)低于对照组,高密度脂蛋白胆固醇(HDL-C)高于对照组,差异有统计学意义(P<0.05)。两组治疗前后BPRS评分、尿素氮(BUN)、肌酐(Cr)、尿酸(UA)、载脂蛋白A1(Apo-A1)、β2-微球蛋白(β2-MG)比较,差异无统计学意义(P>0.05)。结论:在精神分裂症患者治疗中,氯氮平联合齐拉西酮与氯氮平联合利培酮的疗效相近,但氯氮平联合齐拉西酮能显著改善患者的SDSS评分和TESS评分,优化血脂水平和糖代谢指标,降低心血管疾病风险,且对肾功能无明显不良影响。

齐拉西酮对精神分裂症患者认知功能和生活质量的治疗效果研究

目的:探讨齐拉西酮对精神分裂症患者认知功能和生活质量的影响。方法:选择2022年1月至2023年1月该院收治的精神分裂症患者110例作为研究对象,采用随机数字表法分为对照组和观察组,各55例。对照组患者给予利培酮治疗,观察组患者给予齐拉西酮治疗,两组患者均连续治疗8周,治疗期间不使用其他抗精神病药。比较两组患者的临床疗效、简易精神状态检查量表(MMSE)评分、精神分裂症患者生活质量量表(SQLS)评分及不良反应发生情况。结果:观察组、对照组患者的总有效率相近[83.64%(46/55)vs. 89.09%(49/55)],差异无统计学意义(P>0.05)。观察组患者治疗后的MMSE量表评分(定向力评分、即刻记忆评分、延时记忆评分、注意力及计算力评分和语言及视空间能力评分)高于对照组,SQLS量表评分(中心理社会分量表评分、动机/精力分量表评分和症状/不良反应分量表评分)低于对照组,差异均有统计学意义(P<0.05)。观察组患者的不良反应发生率为5.45%(3/55),低于对照组的18.18%(10/55),差异有统计学意义(P<0.05)。结论:齐拉西酮与利培酮治疗精神分裂症的临床疗效相近,但齐拉西酮对认知功能和生活质量的改善效果更为显著,且安全性更高。

利培酮联合喹硫平治疗精神分裂症的临床效果分析

目的:探讨利培酮联合喹硫平治疗精神分裂症的临床效果。方法:选取2023年1—10月天水市第三人民医院收治的精神分裂症患者80例作为研究对象,根据随机数字表法分为对照组与研究组,各40例。对照组采用喹硫平治疗,研究组在对照组基础上采用利培酮治疗。比较两组症状严重程度、治疗效果、不良反应发生情况。结果:治疗前,两组阳性和阴性症状量表(PANSS)评分比较,差异无统计学意义(P>0.05);治疗后,两组PANSS各项评分低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05)。研究组治疗总有效率高于对照组,差异有统计学意义(P=0.006)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论:利培酮联合喹硫平治疗精神分裂症患者的效果显著,可有效改善患者症状,且安全性较高。

齐拉西酮与利培酮治疗精神分裂症对患者认知功能及血清GABA、INH、Ach水平的影响

目的分析精神分裂症患者应用齐拉西酮、利培酮治疗后其认知功能、γ-氨基丁酸(GABA)、抑制素(INH)、乙酰胆碱(Ach)等变化情况。方法采用随机数字表法将100例于2020年6月至2023年6月,从河北省唐山市第五医院精神科选取的精神分裂症患者分为试验组和对照组,各50例。试验组和对照组分别口服盐酸齐拉西酮片、利培酮片,疗程均为2个月。比较两组疗效(治疗2个月后)、精神症状评分、认知功能、神经递质水平(治疗前和治疗2个月后)及安全性(治疗期间)。结果试验组治疗2个月后总有效率为92.00%,高于对照组的76.00%,差异有统计学意义(χ^(2)=4.762,P<0.05)。两组治疗2个月后较治疗前比较,阳性、阴性、精神病理症状评分及总分和血清INH、Ach水平降低,试验组较对照组更低,差异有统计学意义(t=9.449、5.243、20.206、17.310、15.229、7.345,P<0.05);两组治疗2个月后较治疗前比较,即刻、延迟、视觉、延迟视觉记忆评分及总分和血清GABA水平升高,试验组较对照组更高,差异有统计学意义(t=10.657、4.413、3.655、6.451、25.120、11.356,P<0.05)。治疗期间,试验组不良反应发生率为5.00%,低于对照组的26.00%(χ^(2)=4.336,P<0.05)。结论相比利培酮,齐拉西酮可明显升高精神分裂症患者血清GABA水平,降低其血清INH、Ach水平,改善神经功能,同时可改善患者精神症状及认知功能,提高疗效,但二者安全性相当。

利培酮联合丁螺环酮对首发精神分裂症患者临床疗效及安全性的影响

目的:探究利培酮、丁螺环酮联合应用于首发精神分裂症中的临床价值。方法:选取2021年2月—2023年9月石河子绿洲医院精神科二科收治的70例首发精神分裂症患者为研究对象,按照随机数字表法分为对照组(接受利培酮单一治疗)、研究组(在对照组的基础上联合丁螺环酮治疗),各35例。对比两组疗效、临床症状程度、脂代谢指标及不良反应。结果:研究组总有效率(97.14%)高于对照组(77.14%),差异有统计学意义(χ^(2)=6.248,P=0.012);治疗前,两组临床症状程度比较,差异均无统计学意义(P>0.05);治疗后,研究组的临床症状程度均低于对照组,差异均有统计学意义(P<0.05);两组治疗前、治疗后甘油三酯、总胆固醇比较,差异均无统计学意义(P>0.05);研究组不良反应率(11.43%)与对照组(17.14%)比较,差异无统计学意义(χ^(2)=2.540,P=0.111)。结论:利培酮联合丁螺环酮有利于提高临床首发精神分裂症患者的治疗效果,减轻临床症状程度,且具有一定的安全性,不会引起脂代谢异常。

愈癫汤联合利培酮治疗精神分裂症的临床疗效分析

目的分析愈癫汤联合利培酮治疗精神分裂症(SZ)的临床疗效。方法前瞻性选取2021年9月至2023年8月于黑龙江神志医院治疗的SZ患者80例,依据随机数字表法分为试验组(n=40)、对照组(n=40)。对照组给予利培酮治疗,试验组给予愈癫汤联合利培酮治疗,两组均治疗8周。观察两组治疗前、治疗8周后的精神症状、睡眠脑电活动指标[N1期、N3期、睡眠效率(SE)及总睡眠时间(TST)]、血清神经生化指标[脑源性神经营养因子(BDNF)、神经生长相关蛋-43(GAP-43)、瞬时受体电位通道1(TRPC1)]水平以及不良反应。结果治疗8周后,试验组一般精神病理、阳性症状、阴性症状评分及总分分别为(24.75±2.67)、(14.72±1.62)、(14.65±1.60)、(54.12±5.70)分,均低于对照组[(29.73±3.20)、(18.94±2.11)、(18.27±2.06)、(66.94±6.87)分],差异均有统计学意义(P<0.05)。试验组N1期为(39.64±4.14)min,小于对照组[(48.96±5.21)min],N3期眠、SE及TST分别为(85.09±8.78)min、(91.28±9.33)%、(340.28±36.88)min,均大于对照组[(76.46±7.93)min、(80.85±8.43)%、(287.96±30.19)min],差异均有统计学意义(P<0.05)。试验组血清BDNF、GAP-43、TRPC1水平分别为(45.07±4.81)ng/mL、(1.80±0.20)μg/L、(696.28±72.05)pg/mL,均高于对照组[(38.06±4.08)ng/mL、(1.64±0.18)μg/L、(627.96±64.93)pg/mL],差异均有统计学意义(P<0.05)。试验组总有效率为92.50%,大于对照组(72.50%),差异有统计学意义(P<0.05)。试验组不良反应发生率为10.00%,低于对照组(30.00%),差异有统计学意义(P<0.05)。结论愈癫汤联合利培酮治疗SZ可有效改善患者精神症状、睡眠脑电活动及神经生化指标,疗效显著,安全性高。